Securities class action lawsuit filed against Akero Therapeutics for allegedly failing to disclose material info during Class Period, violating federal securities laws.
Securities class action lawsuit filed against Akero Therapeutics (NASDAQ: AKRO) for allegedly failing to disclose material info during Class Period, violating federal securities laws. Investors who bought Akero shares between Sep 13, 2022, and Oct 9, 2023, can apply to be lead plaintiff by Jun 25, 2024. The lawsuit claims Akero and execs provided false statements and omitted key info about lead product candidate, efruxifermin (EFX), in the SYMMETRY study, where around 20% of patients didn't exhibit NASH symptoms.
May 13, 2024
4 Articles